Abstract: A drug delivery device includes a housing component having an interior space and an exterior surface, an injection needle having a retracted state wherein the needle is hosted inside of the interior space and a deployed state wherein a pointed end of the needle projects beyond the exterior surface of the housing component, a needle drive mechanism coupled to the needle to move the needle between the retracted and deployed states, and a drug container disposed within the interior space. The drug container is pre-filled with sterile liquid drug and to be in fluid communication with the needle. The sterile liquid drug herein might be solution, suspension, emulation or other forms in fluid state. The drug delivery device also includes a microcontroller coupled to the needle drive mechanism. The microcontroller is configured to control the needle drive mechanism to move the needle between the retracted state and the deployed state. Further, the delivery device is wearable, disposable, and single-use.

Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.

Abstract: Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated IGF-1, elevated triglyceride levels, and/or elevated CRP levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided. Finally, a method for treating metabolic syndrome is also provided. A hypocaloric or calorie free diet or a fasting mimicking diet is administered for a first time period to the subject to reduce blood pressure or the levels of the above markers/risk factors for aging and age-related diseases.

Abstract: A fasting mimicking diet package providing daily meal portions for a predetermined number of days is provided. The fasting mimicking diet package includes a kale cracker composition, a first vegetable broth composition, a mushroom soup composition, a tomato soup composition, a quinoa-containing minestrone soup composition, a bean-containing minestrone soup composition, and a pumpkin soup composition. Characteristically, the daily meal portions are packaged into meal servings or into a total daily serving to be divided into meals.

Abstract: Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated IGF-1, elevated triglyceride levels, and/or elevated CRP levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided. Finally, a method for treating metabolic syndrome is also provided. A hypocaloric or calorie free diet or a fasting mimicking diet is administered for a first time period to the subject to reduce blood pressure or the levels of the above markers/risk factors for aging and age-related diseases.

Abstract: The present invention relates to a new method for successfully inducing the mutation of cell chemokine receptor CCR5 gene into CCR5?32 deletion gene by using the CRISPR-Cas9 genome editing technique. CCR5 is an important co-receptor for entry of Human Immunodeficiency Virus (HIV) into human host cells. CCR5?32 deletion is a 32-bp deletion in CCR5 coding region, which results in change and premature termination in the sequence following the 185th amino acid. Biallelic homozygous deletion of CCR5?32 is naturally resistant to HIV infection, i.e., the people carrying this mutation can't be infected by HIV. The present invention uses both lentiviral packaging system and the CRISPR technique to induce CCR5?32 deletion. Due to the characteristics of a wide range of Lentivirus infection, the invention can be applied to cells such as bone marrow stem cells and CD4+ T cells and can be expected to be the therapeutic drug for HIV/AIDS infection or other diseases.

Abstract: A network sharing system includes an outdoor wireless transceiver device, an indoor network sharing device, and a high-speed Ethernet transmission cable. The outdoor wireless transceiver device includes a high-frequency network transceiver module and a first Ethernet port and the high-frequency network transceiver module is connected to the first Ethernet port and is configured to receive a high-frequency network signal. The indoor network sharing device includes a processing module and a second Ethernet port. The high-speed Ethernet transmission cable has a transmission rate above 1 giga bits per second (Gbps), two ends of the high-speed Ethernet transmission cable are respectively connected to a first RJ45 connector and a second RJ45 connector, the high-speed Ethernet transmission cable is provided with a flat cable segment, the first RJ45 connector is connected to the first Ethernet port, and the second RJ45 connector is connected to the second Ethernet port.

Abstract: The present invention relates to a DDoS attack detection and mitigation method for an industrial SDN network, and belongs to the field of network security. According to the method, by means of the cooperation between an east-west interface of an SDN controller in an industrial backhaul network and a system manager of an industrial access network, in conjunction with the features of the industrial backhaul network and an industrial access network data packet, a flow entry matching field of an OpenFlow switch is extended, and a flow table 0 is set to be a “flow table dedicated to DDoS attack mitigation” for defending against an attacking data flow in a timely manner. By using the SDN controller of an industrial backhaul network and a DDoS attack detection and mitigation system, an attacking data flow is identified and a DDoS attack source is found, and the policy of mitigating a DDoS attack is implemented by means of scheduling a system manager of the industrial access network.

Abstract: An ultraviolet (UV) light source is provided. The device uses a high-uniformity diode array. A lens unit of collimated illumination lenses is used. A light source of UV light-emitting diode (UVLED) array is formed and passes through the lens unit to uniformly distribute the light source and obtain a collimated light. The present invention comprises a light source of UVLED array; a collimated illumination lens unit; and a substrate. The construction is simple. The present invention can be applied in the lithography of a semiconductor. The lithography forms contact lines of widths not greater than 3 microns (?m); soft-contact lines of widths of 3˜30 ?m; and short-spaced lines of widths of 30˜200 ?m. The present invention avoids the mask from contact wear-out for multiple uses, and further reduces the replacement rate.

Abstract: A system for detecting an illuminance of the present invention includes a light source, a light sensor, and a signal output module. The light source includes a first A light-emitting diode, the first A light-emitting diode having a first color light; and the light source emits a first ray of light. The light sensor has a sensing face; the light sensor includes a first B light-emitting diode disposed on the sensing face, the first B light-emitting diode having the first color light; and the light sensor receives at least a portion of the first ray of light and generates a first sensing voltage. The signal output module is coupled to the light sensor to receive the first sensing voltage and output a sensing result signal according to the first sensing voltage.

Abstract: The present invention provides a composite intelligent biological phototherapy device including a base structure, a plurality of white light fluorescent tubes arranged side by side on the base structure, a plurality of LEDs disposed between the white light fluorescent tubes, a housing having an opening and configured to accommodate the base structure and the white light fluorescent tubes and the LEDs thereon, a light-transmittable plate disposed on the housing corresponding to the opening, and an control module configured to respectively control the white light fluorescent tubes and the LEDs. The base structure includes a plurality of sections, and each of the sections has a first surface facing the light-transmittable plate. The white light fluorescent tubes and the LEDs are provided on the first surfaces, and the sections are bent relative to each other so an angle between the first surfaces of adjacent sections is less than 180 degrees.

Abstract: An automatic injection device is provided herein comprising a container body having a distal end and a proximal end; a piston locked at said proximal end of said container body before medication injection; a spring configured to bias said piston distally; a releasable restraining means configured to releasably restrain said piston in a locked state against said biasing of said spring, wherein, upon release of said releasable restraining means, said piston moves under force of said spring toward said distal end of said container body; an activation means configured to release said releasable means; a needle cap placed at said distal end of said container body; and a needle placed at said distal end of said container body.

Abstract: A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: An Ethernet transmission line includes two RJ45 connectors and a thin connection line. Each RJ45 connector has a connection terminal group, and the connection terminal group includes a first terminal, a second terminal, a third terminal, a fourth terminal, a fifth terminal, a sixth terminal, a seventh terminal, and an eighth terminal that are sequentially arranged. The thin connection line is connected between the two RJ45 connectors and the thin connection line includes a first flexible printed circuit board layer, a second flexible printed circuit board layer, and a spacing layer. The first flexible printed circuit board layer is provided with two first transmission lines respectively electrically connected to the third terminal and the sixth terminal. The second flexible printed circuit board layer is provided with two second transmission lines respectively electrically connected to the fourth terminal and the fifth terminal.

Abstract: A method of treating Alzheimer's associated pathology includes a step of identifying subject having a pathology that is associated with Alzheimer's disease. A fasting mimicking diet (FMD) is then administered to the subject for a first time period. Methods for treating amyloid plaque formation and/or elevated levels of tau protein as well as neuroinflammation are also provided.

Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.